Factores de riesgo que aumentan la probabilidad de experimentar efectos adversos inusuales debido al uso crónico de los inhibidores de la bomba de protones (ibp)

Vista sencilla de ítem
dc.contributor.advisorCastillo Suárez, German David
dc.contributor.advisorVaca Alvarado, Leidy Johana
dc.contributor.authorCuellar Fonseca, Daniela
dc.contributor.authorRamírez Linares, Nathalia
dc.date.accessioned2024-05-15T00:13:33Z
dc.date.available2024-05-15T00:13:33Z
dc.date.issued2024-04
dc.description.abstractLos inhibidores de la bomba de protones (IBP) se encuentran entre los medicamentos más utilizados a nivel mundial por su bajo costo, fácil acceso, alta efectividad y extensa prescripción. Sin embargo, tras su uso crónico se han identificado reacciones adversas inusuales debido al abuso del medicamento, al uso sin justificación terapéutica y al desconocimiento de los factores de riesgo que pueden asociarse al aumento de efectos adversos significativos para la salud. La investigación se centró en una revisión narrativa con uso de elementos sistemáticos para evaluar el equilibrio riesgo-beneficio de estos medicamentos y la información se recopiló de las bases de datos PubMed, Scielo, Scopus y ScienceDirect. Los artículos fueron seleccionados siguiendo la metodología PRISMA para facilitar la identificación y selección de estudios relevantes. De esta manera, fue posible determinar recomendaciones para el uso prudente y racional de los IBP, describir los factores de riesgo que pueden provocar los efectos adversos inesperados que se han descrito en los últimos años por el consumo prolongado y resaltar el papel desempeñado por el Químico Farmacéutico en actividades como atención farmacéutica y farmacovigilancia. Finalmente es necesario continuar la investigación científica debido a que la evidencia actual es limitada, heterogénea y controvertida.
dc.description.abstractenglishProton pump inhibitors (PPIs) are among the most widely used drugs worldwide because of their low cost, easy access, high effectiveness, and widespread prescription. However, following their chronic use, unusual adverse reactions have been identified due to drug abuse, use without therapeutic justification, and lack of knowledge of risk factors that may be associated with an increase in significant adverse health effects. The research focused on a narrative review using systematic elements to evaluate the risk-benefit balance of these drugs and information was collected from PubMed, Scielo, Scopus and ScienceDirect databases. The articles were selected following the PRISMA methodology to facilitate the identification and selection of relevant studies. In this way, it was possible to determine recommendations for the prudent and rational use of PPIs, to describe the risk factors that can cause the unexpected adverse effects that have been described in recent years due to prolonged consumption and to highlight the role played by the Pharmaceutical Chemist in activities such as pharmaceutical care and pharmacovigilance. Finally, it is necessary to continue scientific research because the current evidence is limited, heterogeneous and controversial.
dc.description.degreelevelPregradospa
dc.description.degreelevelQuímico Farmacéuticospa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameUniversidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12112
dc.language.isoes
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programQuímica Farmacéuticaspa
dc.relation.referencesVeettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, Lee YY, Nair AB, Antony PT, Ford AC, Chaiyakunapruk N. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol. 2022. 1551-1566. doi: 10.1111/bcp.15103.
dc.relation.referencesAzpiazu Garrido M, Muñoz Hernández IS. Adecuación y seguridad en el consumo crónico de inhibidores de la bomba de protones. Rev Clin Med Fam. 2017; 10( 2 ): 70-77.
dc.relation.referencesBoghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, Pottie K, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3(3):CD011969. doi:10.1002/14651858.CD011969.pub2.
dc.relation.referencesAguilera-Castro L, Martín-de-Argila-dePrados C, Albillos-Martínez A. Practical considerations in the management of proton-pump inhibitors. Rev Esp Enferm Dig. 2016 Mar;108(3):145-53. doi: 10.17235/reed.2015.3812/2015
dc.relation.referencesGamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol. 2019 (2):114-120. doi: 10.1159/00048850
dc.relation.referencesZuluaga Arbeláez, N., Ardila, Óscar, & Guevara Casallas, L. G. (2022). Uso práctico de inhibidores de bomba de protones. Medicina UPB, 41(1), 61–66. doi: https://doi.org/10.18566/medupb.v41n1.a08
dc.relation.referencesAgüirre-Cardona M, Cardona-Echeverri DM, García-Maürno MA, García-Ospina DA, Gutiérrez-Osorio EA, Castrillón-Spitia JDl. Prescripción-indicación de los inhibidores de la bomba de protones. Costo de la prescripción inadecuada en un primer nivel en Colombia. Acta Medica Colombiana . 2018 ; 43( 4 ): 183-191. doi: https://doi.org/10.36104/amc.2018.1264
dc.relation.referencesCardona-Ospina, JA, Medina-Morales, DA, Rodríguez-Morales, AJ, & Machado-Alba, JE.. Efectos adversos a largo plazo de los inhibidores de la bomba de protones: Perspectiva desde la medicina basada en la evidencia. Revista colombiana de Gastroenterología. (2016): 403-408. doi: https://doi.org/10.22516/25007440.115
dc.relation.referencesPosada Bustos S, De León Fernández N, González Morales R, Tihany Feldman J, Vera Chamorro JF. Prevalencia de prescripción inapropiada de terapia supresora de ácido en adultos hospitalizados en un hospital general de Bogotá. Revista Colombiana de Gastroenterología. 2018; 33( 1 ): 16-21. doi: https://doi.org/10.22516/25007440.236
dc.relation.referencesDos Santos, A. S., de Menezes, S. T., Silva, I. R., Oliveira, W. N., Pereira, M. L., Mill, J. G., Figueiredo, R. C. Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort. BMC nephrology 2023; 24(1):285. doi: 10.1186/s12882-023-03300-4
dc.relation.referencesLodato, F., Poluzzi, E., Raschi, E., Piccinni, C., Koci, A., Olivelli, V., Zoli, M. Appropriateness of proton pump inhibitor prescription in patients admitted to hospital: attitudes of general practitioners and hospital physicians in Italy. European journal of internal medicine 2016; (30):31-36. doi: 10.1016/j.ejim.2016.01.025
dc.relation.referencesPalmowski, L., von Busch, A., Unterberg, M., Bergmann, L., Schmitz, S., Schlüter, A., Rahmel, T. Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study. Critical Care Medicine, 2024; 52(2):190-199. doi: 10.1097/CCM.0000000000006104
dc.relation.referencesDipasquale, V., Cicala, G., Laganà, F., Cutroneo, P., Trimarchi, G., Spina, E., Romano, C. Spontaneous reporting of adverse reactions related to proton pump inhibitors. Digestive and Liver Disease 2023; 55(5):595-600. doi:10.1016/j.dld.2022.10.024
dc.relation.referencesSavarino, V., Dulbecco, P.,Savarino, E. Are proton pump inhibitors really so dangerous?. Digestive and Liver Disease 2016; 48(8):851-859. doi:10.3390/ph16101387
dc.relation.referencesOrtiz-Guerrero G, Amador-Muñoz D, Calderón-Ospina CA, López-Fuentes D, Nava Mesa MO. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plast. 2018; 5257285. doi: 10.1155/2018/5257285
dc.relation.referencesRane, P. P., Guha, S., Chatterjee, S., Aparasu, R. R. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Research in Social and Administrative Pharmacy 2017; 13(2):358-363. doi: 10.1016/j.sapharm.2016.02.012
dc.relation.referencesImparato, R. R., & Toma, T. S. Proton pump inhibitor deprescription: A rapid review. Brazilian Journal of Pharmaceutical Sciences 2022; 58. doi: https://doi.org/10.1590/s2175-97902022e19989
dc.relation.referencesLázaro-Pacheco IB, Servín-Caamaño AI, Pérez-Hernández JL, Rojas-Loureiro G, Servín-Abad L, Tijera FH. PROTON PUMP INHIBITORS INCREASE THE OVERALL RISK OF DEVELOPING BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol. 2018(1):28-32. doi: 10.1590/S0004-2803.201800000-09
dc.relation.referencesJorge, C., Tuna, C., Carlos, P., Ferreira, S., Gonçalves, R., Louro, M. Indicações Terapêuticas e Profiláticas de Uso de Inibidores da Bomba de Protões e Prescrição Inadequada. Medicina Interna 2022;. 29(1):8-12.
dc.relation.referencesVarallo, F. R., de Nadai, T. R., de Oliveira, A. R. A., Carvalho Mastroianni, P. Potential adverse drug events and nephrotoxicity related to prophylaxis with omeprazole for digestive disorders: A prospective cohort study. Clinical Therapeutics 2018; 40(6):973-982. doi: 10.1016/j.clinthera.2018.04.013
dc.relation.referencesForgerini M, Mieli S, Mastroianni PC. Safety assessment of omeprazole use: a review. Sao Paulo Med J. 2018;136(6):557-570. doi: 10.1590/1516-3180.2018.0019220318
dc.relation.referencesRenom-Guiteras, A., Thürmann, P. A., Miralles, R., Klaaßen-Mielke, R., Thiem, U., Stephan, A., RightTimePlaceCare Consortium. Potentially inappropriate medication among people with dementia in eight European countries. Age and ageing 2018; 47(1):68-74. doi: 10.1093/envejecimiento/afx147
dc.relation.referencesBundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2016). BMC Cardiovasc Disord. 2017 (1):3. doi: 10.1186/s12872-016-0453-6
dc.relation.referencesEllis, C. G., & Monge, D. Z. "Efectos adversos del uso crónico de inhibidores de la bomba de protones." Revista Médica Sinergia 6.10 (2021). doi: https://doi.org/10.31434/rms.v6i10.726
dc.relation.referencesCastellana, C., Pecere, S., Furnari, M., Telese, A., Matteo, M. V., Haidry, R., Eusebi, L. H. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med 2021; 131(6):541-549. doi: 10.20452/pamw.15997
dc.relation.referencesHost, L. V., Campochiaro, C., Afonso, A., Nihtyanova, S. I., Denton, C. P., & Ong, V. H. High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. Rheumatology 2021; 60(2):849-854. doi: 10.1093/rheumatology/keaa332
dc.relation.referencesRibiere, S., Guillaumot, M. A., Barré, A., Abou Ali, E., Barret, M., Chaussade, S., Coriat, R. What is the REAL long-term risk of proton pump inhibitors? La Presse Médicale 2019; 48(5):503-510. doi: https://doi.org/10.1016/j.lpm.2019.02.011
dc.relation.referencesChinzon D, Domingues G, Tosetto N, Perrotti M. SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS. Arq Gastroenterol. 2022 (2):219-225. doi: 10.1590/S0004-2803.202202000-40
dc.relation.referencesSankó Posada AA, González Castañeda AP, Vargas Rodríguez LJ, Gordillo Nava GC. Prevalencia de factores de riesgo en pacientes mayores de 50 años con fracturas clásicas de fragilidad atendidos en un hospital de tercer nivel de complejidad en Boyacá. Revista Colombiana de Reumatología. 2021; 28( 2 ): 104-110. doi: https://doi.org/10.1016/j.rcreu.2020.07.008.
dc.relation.referencesXavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol. 2018:243-252. doi: 10.1159/000487154
dc.relation.referencesCarvajal Carlos, PC, Jaimes F. Perfil clínico y demográfico y factores de riesgo frente a la infección por Clostridium difficile. Biomédica. 2017; 37( 1 ): 53-61. doi: https://doi.org/10.7705/biomedica.v37i1.2915.
dc.relation.referencesYu, T., Tang, Y., Jiang, L., Zheng, Y., Xiong, W., Lin, L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Digestive and Liver Disease 2016; 48(4):353-359. doi: 10.1016/j.dld.2015.12.009
dc.relation.referencesLiao S, Gan L, Mei Z. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis. Medicine (Baltimore). 2019 (13):e15011. doi: 10.1097/MD.0000000000015011
dc.relation.referencesFrías Ordoñez, J. S., Arjona Granados, D. A., & Martínez Marín, J. D. Déficit de Vitamina B12 en consumo de Metformina e Inhibidores de Bomba de Protones. Revista Médica De Risaralda. 2022 28(1). doi: https://doi.org/10.22517/25395203.24762
dc.relation.referencesElzouki AN, Neffati N, Rasoul FA, Abdallah A, Othman M, Waness A. Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors. GE Port J Gastroenterol. 2019 (2):83-89. doi: 10.1159/000487963
dc.relation.referencesCasciaro, M., Navarra, M., Inferrera, G., Liotta, M., Gangemi, S., Minciullo, P. L. PPI adverse drugs reactions: a retrospective study. Clinical and Molecular Allergy 2019; 17:1-5. doi: 10.1186/s12948-019-0104-4
dc.relation.referencesMagro, L., Arzenton, E., Leone, R., Stano, M. G., Vezzaro, M., Rudolph, A. Moretti, U. Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database. Frontiers in Pharmacology 2021; 11: 622862. doi: 10.3389/fphar.2020.622862
dc.relation.referencesRameau, A., Lee, M., Andreadis, K., Sulica, L. Perception of Proton Pump Inhibitor Side Effects Among Members of the American Broncho-Esophagological Association. Journal of Voice 2023; 37(5):757-763. doi: 10.1016/j.jvoice.2021.05.006
dc.relation.referencesThreapleton, C. J., Kimpton, J. E., Carey, I. M., DeWilde, S., Cook, D. G., Harris, T., Baker, E. H. Development of a structured clinical pharmacology review for specialist support for management of complex polypharmacy in primary care. British Journal of Clinical Pharmacology 2020; 86(7):1326-1335. doi: 10.1111/bcp.14243
dc.relation.referencesCaetano, C., Veloso, M., & Borda, S. Proton pump inhibitors and dementia: what association?. Dementia & Neuropsychologia, 2023, vol. 17, p. e20220048. doi: https://doi.org/10.1590/1980-5764-DN-2022-0048
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.localAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectInhibidores de la bomba de protones
dc.subjectEfectos adversos
dc.subjectUso crónico
dc.subjectFactores de riesgo
dc.subjectPrescripción
dc.subjectFarmacovigilancia
dc.subjectAtención farmacéutica
dc.subject.ddc615.19
dc.subject.keywordsProton pump inhibitors
dc.subject.keywordsAdverse effects
dc.subject.keywordsChronic use
dc.subject.keywordsRisk factors
dc.subject.keywordsDrug prescriptions
dc.subject.keywordsPharmacovigilance
dc.subject.keywordsPharmaceutical care
dc.titleFactores de riesgo que aumentan la probabilidad de experimentar efectos adversos inusuales debido al uso crónico de los inhibidores de la bomba de protones (ibp)
dc.title.translatedRisk factors that increase the likelihood of experiencing unusual adverse effects due to chronic use of proton pump inhibitors (ppi)
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Pregrado

Archivos

Bloque original
Mostrando 1 - 2 de 2
Miniatura
Nombre:
Trabajo de grado.pdf
Tamaño:
1.77 MB
Formato:
Adobe Portable Document Format
Descargar
Miniatura
Nombre:
Anexo 2 Presentación.pdf
Tamaño:
5.82 MB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Química Farmacéutica